Table 1

 Characteristics of participants at baseline

Exercise group (n = 70)Control group (n = 72)
PD, Parkinson’s disease; SAS, Self-assessment Parkinson’s Disease Disability Scale; UPDRS, Unified Parkinson’s Disease Rating Scale.
*Number of near falls was stated as too large to enumerate for one case in each group.
†Hoehn and Yahr: 2  =  bilateral/midline involvement, no balance impairment; 3 =  impaired righting reactions, mild or moderate disability, capable of leading independent lives; 4  =  severe disability, can walk but marked disability on activities of daily living.
‡UPDRS was not available for one control and two exercise group subjects.
¶Madopar or Sinemet.
§Amantadine, apomorphine, bromocriptine, cabergoline, pergolide, pramipexole, ropinerole.
Values are number (%) unless stated otherwise.
Centre
    Christchurch/Bournemouth33 (47%)34 (47%)
    Poole37 (53%)38 (53%)
Age (y)
    Mean (SD)72.7 (9.6)71.6 (8.8)
    Range44–9152–90
Sex
    Male38 (54%)48 (67%)
    Female32 (46%)24 (33%)
Time since PD diagnosis (y)
    Mean (SD)7.7 (5.8)9.0 (5.8)
    Range1–311–30
No of falls in previous year
    Mean (median)60 (6)61 (5)
    Range2–18202–900
No of near falls in previous year*
    Mean (median)158 (100)193 (100)
    Range0–7000–820
Hoehn and Yahr†
    28 (11%)8 (11%)
    344 (63%)48 (67%)
    418 (26%)16 (22%)
UPDRS‡
    Mean (SD)19.8 (8.3)22.2 (11.9)
    Range3–414–74
SAS
    Mean (SD)56.2 (13.3)57.5 (14.1)
    Range36–9836–92
Living status
    Alone18 (26%)16 (22%)
    With partner43 (61%)52 (72%)
    With family/friends/other9 (13%)4 (6%)
Receiving PD related rehabilitation17 (24%)16 (22%)
Any orthopaedic condition48 (69%)46 (64%)
Any cardiac condition30 (43%)35 (49%)
Any mental health condition13/69 (19%)20/72 (28%)
Taking L-DOPA plus¶62 (89%)57 (79%)
Taking dopamine agonists§36 (49%)49 (68%)